Drug Trial Radar · NCT03599245
This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)
Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,055
Actual
Start
Jul 12, 2018
Primary completion
Jul 17, 2025
Study completion Jul 17, 2025
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jul 26, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple sclerosis (MS) participants who were previously enrolled in a F. Hoffmann-La Roche (Roche) sponsored ocrelizumab phase IIIb/IV trial (i.e. the Parent, P-trial).
Conditions
- Multiple Sclerosis
Interventions
OcrelizumabDrug
Participants will receive a 600-mg infusion of Ocrelizumab every 24 months for two years.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Onset of Confirmed Disability Progression (CDP) Sustained for at Least 24 Weeks From CASTING Baseline to LIBERTO Week 96Time frame: From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
- Time to Onset of CDP Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96Time frame: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
- Time to Onset of CDP Sustained for at Least 48 Weeks From CASTING Baseline to LIBERTO Week 96Time frame: From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
- Time to Onset of CDP Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96Time frame: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
- Percentage of Participants Who Had CDP Sustained for at Least 24 Weeks From CASTING Baseline to LIBERTO Week 96Time frame: From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
- Percentage of Participants Who Had CDP Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96Time frame: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
- Percentage of Participants Who Had CDP Sustained for at Least 48 Weeks From CASTING Baseline to LIBERTO Week 96Time frame: From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
- Percentage of Participants Who Had CDP Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96Time frame: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
- Percentage of Participants Who Had Confirmed Disability Improvement (CDI) Sustained for at Least 24 Weeks From CASTING Baseline to LIBERTO Week 96Time frame: From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
- Percentage of Participants Who Had CDI Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96Time frame: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
- Percentage of Participants Who Had CDI Sustained for at Least 48 Weeks From CASTING Baseline to LIBERTO Week 96Time frame: From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
- Percentage of Participants Who Had CDI Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96Time frame: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
- Percentage of Participants Who Had Improved, Stable or Worsened Disability Compared With CASTING Baseline in EDSS Category at LIBERTO Week 96Time frame: At LIBERTO Week 96
- Percentage of Participants Who Had Stable or Worsened Disability Compared With ENSEMBLE Baseline in EDSS Category at LIBERTO Week 96Time frame: At LIBERTO Week 96
- Change From CASTING Baseline in EDSS Score to LIBERTO Week 96Time frame: CASTING Baseline to LIBERTO Week 96 (up to 4 years)
- Change From ENSEMBLE Baseline in EDSS Score to LIBERTO Week 96Time frame: ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
- Time to ≥ 20% Increase in 25-foot Walk Test (T25FWT) Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96Time frame: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
- Time to ≥ 20% Increase in 25FWT Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96Time frame: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
- Time to ≥ 20% Increase in 9 Hole Peg Test (9HPT) Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96Time frame: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
- Time to ≥ 20% Increase in 9HPT Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96Time frame: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
- Percentage of Participants With ≥ 20% Increase in T25FWT Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96Time frame: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
- Percentage of Participants With ≥ 20% Increase in T25FWT Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96Time frame: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
- Percentage of Participants With ≥ 20% Increase in 9HPT Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96Time frame: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
- Percentage of Participants With ≥ 20% Increase in 9HPT Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96Time frame: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Locations
161 sites in 26 countries. Site status is shown where the registry gives one.
Hospital Churruca Visca
Buenos Aires, Argentina
Centro de Especialidades Neurológicas y Rehabilitación - CENyR
Ciudad Autonoma Buenos Aires, Argentina
Fundacion Rosarina de Neurorehabilitacion
Rosario, Argentina
AZ Sint Jan
Bruges, Belgium
UZ Antwerpen
Edegem, Belgium
CHU Tivoli
La Louvière, Belgium
CHU de Liège (Sart Tilman)
Liège, Belgium
Revalidatie en MS Centrum
Overpelt, Belgium
Instituto de Neurologia de Curitiba
Curitiba, Paraná, Brazil
Hospital Sao Lucas - PUCRS
Porto Alegre, Rio Grande do Sul, Brazil
Hospital das Clinicas - FMUSP
São Paulo, São Paulo, Brazil
Shat Np Sveti Naum
Sofia, Bulgaria
Multiprofile Hosp. for Active Treatment
Sofia, Bulgaria
University of British Columbia
Vancouver, British Columbia, Canada
London Health Sciences Centre Uni Campus
London, Ontario, Canada
The Ottawa Hospital - General Campus
Ottawa, Ontario, Canada
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Clinique NeuroOutaouais
Gatineau, Quebec, Canada
Recherche Sepmus Inc.
Greenfield Park, Quebec, Canada
Montreal Neurological Institute and Hospital
Montreal, Quebec, Canada
Clinical Hospital Centre Zagreb
Zagreb, Croatia
Fakultni nemocnice u sv. Anny
Brno, Czechia
Nemocnice Jihlava
Jihlava, Czechia
VFN Praha Poliklinika Rs Centrum - Budova A
Prague, Czechia
Fakultni nemocnice v Motole
Prague, Czechia
Aalborg Universitetshospital
Aalborg, Denmark
Aarhus Universitetshospital
Aarhus N, Denmark
Rigshospitalet Glostrup
Glostrup Municipality, Denmark
Odense Universitetshospital, Neurologisk Afdeling N
Odense C, Denmark
Hjerne- og nervesygdomme, Ambulatorium, Skleroseklinikken
Sønderborg, Denmark
East Tallinn Central Hospital
Tallinn, Estonia
West Tallinn Central Hospital
Tallinn, Estonia
Tartu University Hospital
Tartu, Estonia
Mehiläinen Neo Turku
Turku, Finland
CHU de Besancon Hopital Jean Minjoz
Besançon, France
Groupe Hospitalier Pellegrin
Bordeaux, France
Hopital neurologique Pierre Wertheimer - CHU Lyon
Bron, France
Hopital Gabriel Montpied CHU de Clermont-Ferrand
Clermont-Ferrand, France
CH de Gonesse
Gonesse, France
CHU de Grenoble
La Tronche, France
Showing 40 of 161 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.